Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dravet Syndrome: full-pipeline trial registry
5 of 13 indexed Dravet Syndrome trials are currently recruiting.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 5 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Dravet Syndrome: 13 US clinical trials tracked, 5 recruiting.
Dravet Syndrome is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Longboard Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition dravet-syndrome
OPEN 5 | RECR 38% | LATE 6 | EARLY 6 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Dravet Syndrome lists 5 open slots (38% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dravet Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dravet Syndrome is recruiting below its size-band peers.
5 of 13 indexed trials (38.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Dravet Syndrome research.
Longboard Pharmaceuticals accounts for 3 of 13 trials (23.1%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Dravet Syndrome trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Dravet Syndrome research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Stoke Therapeutics
NCT06872125
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Longboard Pharmaceuticals
NCT06660394
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
NCT04462770
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
NCT05419492
GABA Biomarkers in Dravet Syndrome
Cook Children's Health Care System
NCT05651204
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals
NCT05044819
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
Stoke Therapeutics
NCT04740476
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
UCB Biosciences
NCT06118255
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Zogenix
NCT03936777
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals
NCT05364021
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
NCT05626634
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
Zogenix International Limited, Inc., a subsidiary of Zogenix
NCT03467113
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
Gillette Children's Specialty Healthcare
NCT01607073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Dravet Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dravet Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dravet Syndrome page
13 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Dravet Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Longboard Pharmaceuticals sponsors the most Dravet Syndrome trials on record, review their full trial history before evaluating a specific study. See Longboard Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dravet Syndrome condition card totals 13 registered trials; most-linked intervention Placebo; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.